Drug intelligence / Profile preview

PVS-101

Development stage: Unknown
Lead developer: Takeda
Modality: Cell Therapies

Overview

PVS-101 is a novel endothelial cell therapy developed by Pervasis Therapeutics, which was later acquired by Shire. This cell-based therapy is designed for vascular trauma repair, aiming to address unmet needs in vascular healing. It was in late-stage Phase 1/2 clinical development for its primary indication.

Beyond the preview

Go deeper on PVS-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PVS-101.

Explore the full profile